Authors: SZAMEL I HINDY I BUDAI B KANGAS L HAJBA A LAMMINTAUSTA R

Citation: I. Szamel et al., ENDOCRINE MECHANISM OF ACTION OF TOREMIFENE AT THE LEVEL OF THE CENTRAL-NERVOUS-SYSTEM IN ADVANCED BREAST-CANCER PATIENTS, Cancer chemotherapy and pharmacology, 42(3), 1998, pp. 241-246

Authors: SZAMEL I HINDY I BUDAI B KANGAS L HAJBA A LAMMINTAUSTA R

Citation: I. Szamel et al., ENDOCRINE EFFECTS OF TOREMIFENE (TOR) AT THE LEVEL OF CNS IN ADVANCEDBREAST-CANCER PATIENTS, European journal of cancer, 33, 1997, pp. 683-683

Authors: PYRHONEN S VALAVAARA R MODIG H PAWLICKI M PIENKOWSKI T GUNDERSEN S BAUER J WESTMAN G LUNDGREN S BIANCO G MELLA O NILSSON I HIETANEN T HINDY I VUORINEN J HAJBA A

Citation: S. Pyrhonen et al., COMPARISON OF TOREMIFENE AND TAMOXIFEN IN POSTMENOPAUSAL PATIENTS WITH ADVANCED BREAST-CANCER - A RANDOMIZED DOUBLE-BLIND, THE NORDIC PHASE-III STUDY, British Journal of Cancer, 76(2), 1997, pp. 270-277

Authors: SZAMEL I HINDY I BUDAI B KANGAS L HAJBA A LAMMINTAUSTA R

Citation: I. Szamel et al., LHRH AGONIST ANALOG FUNCTIONAL TEST IN ADVANCED BREAST-CANCER PATIENTS TREATED WITH TOREMIFENE(TOR), European journal of cancer, 31A, 1995, pp. 371-371

Authors: SZAMEL I HINDY I VINCZE B ECKHARDT S KANGAS L HAJBA A

Citation: I. Szamel et al., INFLUENCE OF TOREMIFENE ON THE ENDOCRINE REGULATION IN BREAST-CANCER PATIENTS, European journal of cancer, 30A(2), 1994, pp. 154-158

Authors: PYRHONEN S VALAVAARA R VUORINEN J HAJBA A

Citation: S. Pyrhonen et al., HIGH-DOSE TOREMIFENE IN ADVANCED BREAST-CANCER RESISTANT TO OR RELAPSED DURING TAMOXIFEN TREATMENT, Breast cancer research and treatment, 29(3), 1994, pp. 223-228